| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1050956975 |
| P356 | DOI | 10.1186/S40413-016-0112-5 |
| P3181 | OpenCitations bibliographic resource ID | 4737295 |
| P932 | PMC publication ID | 4924237 |
| P698 | PubMed publication ID | 27386041 |
| P50 | author | Hans-Uwe Simon | Q37370697 |
| Tara F Carr | Q64683172 | ||
| P2093 | author name string | Lanny J Rosenwasser | |
| Bruce S Bochner | |||
| Sergejs Berdnikovs | |||
| P2860 | cites work | A novel and highly divergent homolog of human eosinophil granule major basic protein | Q22009546 |
| Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases | Q26767423 | ||
| Novel Therapies for Eosinophilic Disorders | Q26799600 | ||
| Activation states of blood eosinophils in asthma | Q26853383 | ||
| EMR1, the human homolog of F4/80, is an eosinophil-specific receptor | Q28247107 | ||
| The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders | Q28307714 | ||
| Non-eosinophilic asthma: importance and possible mechanisms | Q28394141 | ||
| Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis | Q33693224 | ||
| Eosinophil extracellular DNA traps in skin diseases | Q33787694 | ||
| Glycomic analysis of human mast cells, eosinophils and basophils | Q33949464 | ||
| Novel targeted therapies for eosinophil-associated diseases and allergy | Q34444620 | ||
| Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity | Q34479428 | ||
| The eosinophil | Q34503956 | ||
| Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways | Q34899214 | ||
| Tucson Children's Respiratory Study: 1980 to present | Q35110736 | ||
| Eosinophils: changing perspectives in health and disease | Q35170969 | ||
| Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation | Q35569801 | ||
| Eosinophils in chronically inflamed human upper airway tissues express transforming growth factor beta 1 gene (TGF beta 1). | Q35602823 | ||
| Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics | Q36001230 | ||
| Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8 | Q36139731 | ||
| Eosinophil peroxidase-induced mast cell secretion | Q36343960 | ||
| α(M)β(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin. | Q36842950 | ||
| Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation | Q36853164 | ||
| Tissue and BAL based biomarkers in asthma | Q36998180 | ||
| Clinical heterogeneity in the severe asthma research program | Q37651783 | ||
| Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. | Q37694601 | ||
| Eosinophils in health and disease: the LIAR hypothesis | Q37743621 | ||
| Targeting eosinophils in allergy, inflammation and beyond | Q38075409 | ||
| Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. | Q38169245 | ||
| International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma | Q38171268 | ||
| Eosinophil granule proteins: form and function | Q38209847 | ||
| Pathobiology of severe asthma | Q38271260 | ||
| Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care | Q38348052 | ||
| High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma | Q39091847 | ||
| Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials | Q41452053 | ||
| Innate antifungal immunity of human eosinophils mediated by a beta 2 integrin, CD11b | Q41819302 | ||
| Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action | Q41852585 | ||
| Dissection of the hyperadhesive phenotype of airway eosinophils in asthma | Q41975092 | ||
| Activation of basophil and mast cell histamine release by eosinophil granule major basic protein | Q41991407 | ||
| Human airway smooth muscle promotes eosinophil differentiation | Q42170514 | ||
| CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status | Q43758988 | ||
| Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. | Q44247874 | ||
| Sputum CD34+IL-5Ralpha+ cells increase after allergen: evidence for in situ eosinophilopoiesis | Q44663899 | ||
| IL-3 and IL-5 prime normal human eosinophils to produce leukotriene C4 in response to soluble agonists | Q44813751 | ||
| Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics | Q44863693 | ||
| Asthma biomarkers: what constitutes a 'gold standard'? | Q44944320 | ||
| Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni | Q45018920 | ||
| Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. | Q45755848 | ||
| Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial | Q47249808 | ||
| Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation | Q47275002 | ||
| Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin | Q47401930 | ||
| Mepolizumab treatment in patients with severe eosinophilic asthma | Q48065984 | ||
| Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes | Q48122852 | ||
| Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. | Q51026334 | ||
| High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. | Q51247351 | ||
| Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. | Q51611177 | ||
| Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. | Q51699006 | ||
| Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples | Q60624769 | ||
| Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense | Q61959753 | ||
| Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study | Q68868960 | ||
| IL-8 is expressed by human peripheral blood eosinophils. Evidence for increased secretion in asthma | Q72191734 | ||
| Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics | Q73271383 | ||
| Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma | Q73728083 | ||
| The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions | Q74108345 | ||
| Cytolysis and piecemeal degranulation as distinct modes of activation of airway mucosal eosinophils | Q77178490 | ||
| Counterpoint: Is measuring sputum eosinophils useful in the management of severe asthma? No, not for the vast majority of patients | Q84302499 | ||
| Eosinophil granule protein localization in eosinophilic endomyocardial disease | Q84551006 | ||
| Correlation between CCL26 production by human bronchial epithelial cells and airway eosinophils: Involvement in patients with severe eosinophilic asthma | Q87234140 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 21 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | The World Allergy Organization Journal | Q15756346 |
| P1476 | title | Eosinophilic bioactivities in severe asthma | |
| P478 | volume | 9 |
| Q57284070 | A review of inflammatory mechanism in airway diseases |
| Q89638365 | Assessment of levels of asthma control among adult patients with asthma at Chitungwiza Central Hospital, Zimbabwe |
| Q41356690 | Biomarkers in inflammometry pediatric asthma: utility in daily clinical practice. |
| Q42136802 | Cell Penetrating Peptide Derived from Human Eosinophil Cationic Protein Decreases Airway Allergic Inflammation |
| Q33785627 | Eosinophil Activation Status in Separate Compartments and Association with Asthma |
| Q47732959 | Eosinophil persistence in vivo and sustained viability ex vivo in response to respiratory challenge with fungal allergens. |
| Q40046428 | Eosinophilic and Non-Eosinophilic Asthma. |
| Q92751812 | Eosinophils capture viruses, a capacity that is defective in asthma |
| Q47273537 | Eosinophils promote inducible NOS-mediated lung allograft acceptance |
| Q37200161 | Eosinophils, galectins, and a reason to breathe |
| Q92786997 | Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma |
| Q92218959 | Genetic association of interleukin 18 (-607C/A, rs1946518) single nucleotide polymorphism with asthmatic children, disease severity and total IgE serum level |
| Q57028409 | Impact of eosinophil-peroxidase (EPX) deficiency on eosinophil structure and function in mouse airways |
| Q50199742 | Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. |
| Q39377433 | Regulation of Eosinophil Recruitment and Activation by Galectins in Allergic Asthma |
| Q59351075 | STAT6 inhibitory peptide reduces dendritic cell migration to the lymph nodes to control Th2 adaptive immunity in the mouse lung |
| Q58795817 | The prostaglandin D receptor 2 pathway in asthma: a key player in airway inflammation |
| Q48335095 | The role of upper airway pathology as a co-morbidity in severe asthma. |
| Q48091478 | Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea |
| Q49380897 | Toll-Interacting Protein, Tollip, Inhibits IL-13-Mediated Pulmonary Eosinophilic Inflammation in Mice |
| Q64062566 | Use of Symptoms Scores, Spirometry, and Other Pulmonary Function Testing for Asthma Monitoring |
| Q42328580 | World Allergy Organization Journal: the Editors Look Back at 2016. |
Search more.